Impact of CES1 Genotype on Metabolism of Methylphenidate

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether differences in the gene coding for the liver enzyme carboxylesterase 1 (CES1) means differences in the metabolism of methylphenidate, a CES1 dependent drug.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bispebjerg Hospital
• Collaborators: Duke University; Mental Health Centre Sct. Hans (Denmark); The Leiden Academic Center for Drug Research (LACDR); The Ministry of Science, Technology and Innovation, Denmark; University of Copenhagen
• Treatments: Methylphenidate

Criteria

Inclusion Criteria:

• > 18 years old

• Caucasian

Exclusion Criteria:

• Chronic disease (except hay fever and eczema)

• Pregnancy

• Smoking

• High level of alcohol consumption (> 21 units per week for men and 14 for women)

• Known allergy towards methylphenidate

• Permanent use of medication (contraception ok)